The diagnosis of diabetes often feels like a sudden shock – one day you’re fine, the next you’re facing a lifelong condition. But the reality is far more insidious. Diabetes doesn’t appear overnight.

Type 2 diabetes operates like a master of deception, quietly wreaking havoc throughout your body while maintaining an facade of normalcy that can persist for years or even decades. This silent ...

ORLANDO, Fla. — The old, generic cholesterol drug fenofibrate has shown potential for slowing the progression of diabetic retinopathy in people with early retinal changes, with the potential to reduce ...

Among those who have had gestational diabetes, about 35% will develop type 2 diabetes within a decade. A new study led by Dr. Saifur Khan, Ph.D., cardiology research faculty member at the University ...

Among diabetes progression indicators, kidney cancer risk was highest for patients with chronic kidney disease and diabetes duration of at least 5 years. People with a progressive form of diabetes are ...

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or ...

In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of DR progression compared ...

Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that. In a new decades-long study, ...

ORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. Fenofibrate also reduced the chance of any progression of ...